prikaz prve stranice dokumenta Uloga redoks ravnoteže u razvoju kemorezistencije
Access restricted to students and staff of home institution
undergraduate thesis
Uloga redoks ravnoteže u razvoju kemorezistencije
2021. urn:nbn:hr:193:912443
Baćac, Antonela
University of Rijeka
Faculty of Biotechnology and Drug Development

Cite this document

Baćac, A. (2021). Uloga redoks ravnoteže u razvoju kemorezistencije (Undergraduate thesis). Rijeka: University of Rijeka. Retrieved from https://urn.nsk.hr/urn:nbn:hr:193:912443

Baćac, Antonela. "Uloga redoks ravnoteže u razvoju kemorezistencije." Undergraduate thesis, University of Rijeka, 2021. https://urn.nsk.hr/urn:nbn:hr:193:912443

Baćac, Antonela. "Uloga redoks ravnoteže u razvoju kemorezistencije." Undergraduate thesis, University of Rijeka, 2021. https://urn.nsk.hr/urn:nbn:hr:193:912443

Baćac, A. (2021). 'Uloga redoks ravnoteže u razvoju kemorezistencije', Undergraduate thesis, University of Rijeka, accessed 20 January 2025, https://urn.nsk.hr/urn:nbn:hr:193:912443

Baćac A. Uloga redoks ravnoteže u razvoju kemorezistencije [Undergraduate thesis]. Rijeka: University of Rijeka; 2021 [cited 2025 January 20] Available at: https://urn.nsk.hr/urn:nbn:hr:193:912443

A. Baćac, "Uloga redoks ravnoteže u razvoju kemorezistencije", Undergraduate thesis, University of Rijeka, Rijeka, 2021. Available at: https://urn.nsk.hr/urn:nbn:hr:193:912443

Please login to the repository to save this object to your list.
Metadata
TitleUloga redoks ravnoteže u razvoju kemorezistencije
Title (english)The role of redox balance in development of chemoresistance
AuthorAntonela Baćac
MentorMirela Sedić (mentor)
Committee memberDean Marković (predsjednik povjerenstva)
Committee memberSanja Dević Pavlić (član povjerenstva)
GranterUniversity of Rijeka
(Faculty of Biotechnology and Drug Development)
Rijeka
Defense date and country2021-09-22, Croatia
Scientific / art field,
discipline and subdiscipline		BIOTECHNICAL SCIENCES
Biotechnology
Abstract
Kemoterapeutski lijekovi imaju sposobnost stvaranja reaktivnih vrsta koje se vežu za određene strukture unutar stanice raka i potiču staničnu smrt. Redoks homeostaza stanica raka poremećena je zbog kontinuirane izloženosti kemoterapijskim sredstvima, što može rezultirati promjenom sposobnosti stanice da se nosi s prekomjernom razinom reaktivnih vrsta. Kako bi se nosile s oksidativnim stresom, stanice raka kontroliraju povišenu razinu reaktivnih vrsta pojačavajući aktivnost staničnih antioksidativnih sustava. Antioksidativni strojevi sprječavaju staničnu smrt i potiču razvoj tumora dok su istodobno stanice otpornije na egzogeni stimulans poput kemoterapije i radioterapije. Pojačani antioksidativni kapacitet stanica raka ključna je odrednica razvoja rezistencije na kemoterapiju. Otpornost na lijekove razvija se u gotovo svih bolesnika s rakom debelog crijeva, što dovodi do smanjenja terapijske učinkovitosti antikancerogenih sredstava. Nuklearni faktor eritroid 2 povezan s faktorom 2 (engl. nuclear factor erythroid 2-related factor 2, Nrf2) glavni je regulator neutraliziranja staničnih reaktivnih kisikovih vrsta (engl. reactive oxygen species, ROS) i obnavljanja redoks ravnoteže. Nrf2 regulira ekspresiju antioksidativnih gena, gena za metabolizam i detoksikaciju te gena koji kodiraju transportere. Aktivacija Nrf2 može dovesti do progresije raka, invazije, metastaza i kemorezistencije. Nrf2 igra ključnu ulogu u rezistenciji na kemoterapiju potičući metabolizam lijekova ili izbacivanje lijekova iz stanice. Ekspresija Nrf2 često je povećana u različitim vrstama kemorezistentnih stanica raka, stoga blokiranje aktivnosti Nrf2 u malignim stanicama predstavlja značajan pristup za prevenciju raka.
Abstract (english)
Chemotherapeutic drugs have the ability to produce reactive species that bind to certain structures within a cancer cell and promote cell death. The redox homeostasis of cancer cells is disrupted due to continuous exposure to chemotherapeutic agents. To overcome oxidative stress, cancer cells control elevated levels of reactive species by enhancing the activity of cellular antioxidant systems. Highly compatible antioxidant machinery prevent cell death and promote tumor development, while at the same time cells are more resistant to exogenous stimulants such as chemotherapy and radiotherapy. Enhanced antioxidant capacity of cancer cells is a key determinant of the development of resistance to chemotherapy. Drug resistance develops in almost all patients with colon cancer leading to a decrease in the therapeutic efficacy of anticancer agents. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a major regulator of neutralizing cellular ROS and restoring redox balance. Nrf2 regulates the expression of antioxidant genes, metabolic and detoxification genes, and transporters. Due to the dual role of Nrf2 in cancer cells, activation of Nrf2 can lead to cancer progression, invasion, metastasis, and chemoresistance. Nrf2 plays a key role in chemotherapy resistance by stimulating drug metabolism or drug efflux. Expression of Nrf2 is often increased in several types of chemoresistant cancer cells, so blocking Nrf2 activity in malignant cells represents a significant approach to cancer prevention.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:193:912443
Study programmeTitle: Biotechnology and drug research
Study programme type: university
Study level: undergraduate
Academic / professional title: sveučilišni/a prvostupnik/prvostupnica biotehnologije i istraživanja lijekova (sveučilišni/a prvostupnik/prvostupnica biotehnologije i istraživanja lijekova)
Type of resourceText
File originBorn digital
Access conditionsAccess restricted to students and staff of home institution
Terms of useLicence In copyright icon
Created on2021-09-27 19:00:07